The biotech is developing drugs that target the biology of aging to treat obesity, cardiovascular disease, and more ...

Scientists at Nagoya University in Japan have identified the genes that allow an organism to switch between living as single ...

Lattice Semiconductor’s updated story in the market now centres on a higher price target range of US$75 to US$85, while the model fair value estimate holds steady at US$81.23 and the long run revenue ...

The Center for the Rehabilitation of Wildlife on Sanibel kicks off its annual speaker series with a python elimination expert ...

Cogent Biosciences (COGT) shares have surged after pivotal bezuclastinib data in imatinib-resistant aGIST, demonstrating significant mPFS and ORR improvements over sunitinib alone. Bezuclastinib’s ...

Evidence suggests pythons may be evolving to tolerate colder climates farther north. These invasive snakes are primarily established in South Florida, south of Lake Okeechobee. As sections of the ...

Ensysce Biosciences ( (ENSC)) has provided an announcement. On November 14, 2025, Ensysce Biosciences closed a $4 million convertible preferred stock financing, with the potential for an additional ...

Pacira BioSciences (PCRX) edged higher by 0.4% after an investor pushed the company to explore a sale process. "Due to what we believe is management's unrelenting underperformance, out-of-control ...

Parse Biosciences co-founders are CTO Charles Roco and CEO Alex Rosenberg. (Parse Photo) Seattle’s Parse Biosciences is teed up for an acquisition by Qiagen, a Netherlands-based holding company, in a ...

Novartis NOVN-0.18%decrease; red down pointing triangle is acquiring Avidity Biosciences RNA 0.05%increase; green up pointing triangle in a $12 billion deal that the Swiss drugmaker said would further ...

Swiss drugmaker Novartis on Sunday said it agreed to acquire US biotech firm Avidity Biosciences for about $12 billion in cash, as the company looks to bolster its portfolio of treatments for rare ...

(Reuters) -Novartis AG is close to acquiring U.S. biotech Avidity Biosciences for more than $70 per share, Bloomberg News reported, citing a person familiar with the matter who said an announcement ...